The approval includes a REMS program because some patients experience a worrying drop in left ventricular ejection fraction.
The long-anticipated, delayed FDA approval of mavacamten finally happened. But the path forward for Bristol Myers Squibb drug for obstructive hypertrophic cardiomyopathy (HCM) is far from clear.
The company is selling the drug under the name Camzyos. The original PDUFA date — the date by which the FDA is supposed to make a decision — for mavacamten was Jan. 28. In November 2021, the agency moved the decision date to April 28.
The approval of mavacamten is noteworthy because it is a first-in-class drug that is designed to treat the underlying dysfunction of cardiac muscle cells that leads to hypertrophy (thickening) of the heart muscle. The prevalence of HCM is about 1 in 500, according to one frequently cited study that usedelectrocardiograms to screen people. Other studies have found it to be more common.
Before the announcement of the approval last night, Wall Street analysts had projected mavacamten would easily be a blockbuster with annual sales of $2 billion. But Bristol Myers Squibb CEO Giovanni Caforio and other company officials held an earnings call this morning that included news of dipping sales of Revlimid (lenalidomide) because of biosimilars coming on the market, so the company’s stock price was on track to close at a price lower than yesterday’s price.
Reuters and several other news outlets reported that Bristol Myers Squibb is pricing mavacamten at $89,500 a year, which is six times higher than the $12,000-$15,000 price range suggestedby Institute for Clinical and Economic Review when it conducted its cost-effectiveness review of mavacamten last year.
The mavacamten works by reducing the contraction of heart muscles. In some patients that goes effect goes too far and results in heart failure. The FDA’s approval of the drug includes a requirement that it only be available through a Risk Evaluation and Mitigation Strategy (REMS) program. Approvals tied to REMS programs are common for drugs that have serious side effects.
The REMS program for mavacamtem means prescribers and patients must enroll in the program. Pharmacies must also be certified and can only dispense the drug to patients who have are enrolled in the program.
According to the press release issued by Bristol Myers Squibb about the mavacamten approval, seven (6%) patients in the mavacamten group in the pivotal phase 3 trail experienced drops in left ventricular ejection fraction to below 50%, a marker for heart failure. The press release said all seven recovered when they stopped taking mavacamten.
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care two share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More